Intelligence · Clinical Pipeline
BioMarin Pharmaceutical Australia Pipeline
All ClinicalTrials.gov programs at BioMarin Pharmaceutical Australia — phase, modality, and trial IDs.
- Programs
- 8
Quick answer
BioMarin Pharmaceutical Australia has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
BMN 111 administration via Injector Pen
BioMarin Pharmaceutical Australia Pty Ltd
Achondroplasia
1 trial -
BMN 255
BioMarin Pharmaceutical Australia Pty Ltd
Hyperoxaluria
1 trial -
BMN 349
BioMarin Pharmaceutical Australia Pty Ltd
Alpha 1-Antitrypsin Deficiency
1 trial -
Cisplatin
BioMarin Pharmaceutical Australia Pty Ltd
Solid Tumors
1 trial -
PARP inhibitor BMN-673
BioMarin Pharmaceutical Australia Pty Ltd
Metastatic Cancer
1 trial -
Talazoparib
BioMarin Pharmaceutical Australia Pty Ltd
Childhood Solid Tumors
1 trial -
Tetrahydrobiopterin 10 mg/kg
BioMarin Pharmaceutical Australia Pty Ltd
Claudication, Intermittent
1 trial -
sapropterin dihydrochloride (6R-BH4)
BioMarin Pharmaceutical Australia Pty Ltd
Pulmonary Arterial Hypertension
1 trial
Frequently asked questions
How many pipeline programs does BioMarin Pharmaceutical Australia have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs